These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 26891424

  • 41. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
    Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group.
    Eur J Clin Pharmacol; 2011 Oct; 67(10):1061-7. PubMed ID: 21538145
    [Abstract] [Full Text] [Related]

  • 42. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
    Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K.
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):485-92. PubMed ID: 19877972
    [Abstract] [Full Text] [Related]

  • 43. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
    Wang LJ, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Shyu YC.
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
    [Abstract] [Full Text] [Related]

  • 44. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
    Liao HC, Lin FJ, Hsu CN, Gau SS, Wang CC.
    J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [Abstract] [Full Text] [Related]

  • 46. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
    van den Ban E, Souverein PC, Swaab H, van Engeland H, Egberts TC, Heerdink ER.
    Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
    [Abstract] [Full Text] [Related]

  • 47. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z, Yuan J, Pei X, Zhang K, Xu C, Hu N, Xie R, Zhao Y, Wang Y, Yang L, Cao Q.
    Int J Neuropsychopharmacol; 2022 Sep 28; 25(9):709-719. PubMed ID: 35524732
    [Abstract] [Full Text] [Related]

  • 48. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.
    Curr Med Res Opin; 2011 Sep 28; 27 Suppl 2():35-44. PubMed ID: 21787126
    [Abstract] [Full Text] [Related]

  • 49. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
    Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H, Vertreter der deutschen C-2000-045-Studiengruppe.
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul 28; 34(4):257-65. PubMed ID: 16927568
    [Abstract] [Full Text] [Related]

  • 50. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B.
    Child Psychiatry Hum Dev; 2011 Jun 28; 42(3):257-69. PubMed ID: 21165694
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. ADHD Medication Trends in Turkey: 2009-2013.
    Öner Ö, Yilmaz EŞ, Karadağ H, Vural M, Vural EH, Akbulat A, Gürsöz H, Türkçapar H, Kerman S.
    J Atten Disord; 2017 Dec 28; 21(14):1192-1197. PubMed ID: 24554298
    [Abstract] [Full Text] [Related]

  • 53. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC, Wan GJ, Kemner JE, Olfson M.
    Arch Pediatr Adolesc Med; 2005 Jun 28; 159(6):572-8. PubMed ID: 15939858
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS, Shang CY, Lin HY, Gau SS.
    J Child Adolesc Psychopharmacol; 2021 Apr 28; 31(3):187-196. PubMed ID: 33890819
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
    Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE.
    J Child Adolesc Psychopharmacol; 2009 Oct 28; 19(5):493-9. PubMed ID: 19877973
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.